Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

S. Morales,Antonio Lorenzo,Manuel Ramos,Pedro Ballesteros,Miguel Méndez,C. Almanza,Javier Castellanos,José Andrés Moreno Nogueira,J. Casal,José Lizón,Amparo Oltra,Adolfo Frau,Ignacio Machengs,A. Galan,J. Belon,Cristina Llorca

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

2004

S. Morales
Antonio Lorenzo
Manuel Ramos
Pedro Ballesteros
Miguel Méndez
C. Almanza
Javier Castellanos
José Andrés Moreno Nogueira
J. Casal
José Lizón
Amparo Oltra
Adolfo Frau
Ignacio Machengs
A. Galan
J. Belon
Cristina Llorca

Purpose In this multicentre phase II study, the efficacy and safety profile of the combination of docetaxel and epirubicin as first-line chemotherapy for metastatic breast cancer (MBC) were evaluated.

Keywords:

Breast cancer
Cancer
Phases of clinical research
Epirubicin
Metastasis
Oncology
Metastatic breast cancer
Docetaxel
Internal medicine
Chemotherapy
Medicine
Neutropenia
Febrile neutropenia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations